Live feed08:00:00·564dPRReleasevia QuantisnowBiomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute LeukemiaByQuantisnow·Wall Street's wire, on your screen.BMEA· Biomea Fusion Inc.Health Care
